FDA Approves Shock Wave Device for Treatment of Diabetic Foot Ulcers
Summary: The U.S. FDA granted approval to the Dermapace System (Sanuwave Health), a noninvasive extracorporeal shock wave therapy device, for treating chronic, full-thickness diabetic foot ulcers. The device delivers focused acoustic pressure waves to stimulate wound healing through mechanical stress, angiogenesis promotion, and increased blood flow.
Key Highlights:
- First shock wave device specifically approved for DFU indication
- Noninvasive, office-based treatment option
- Targets hard-to-heal chronic diabetic foot ulcers
- Provides alternative or adjunct to standard wound care
Keywords: shock wave therapy DFU, Dermapace, extracorporeal shock wave